| 徐璐璐,沈伟伟,陈潇潇,李桂霞,许圆圆,高眉扬,周素娟,林海江,何纳.台州市2016-2018年新报告HIV/AIDS抗病毒治疗前HIV-1耐药及亚型流行特征分析[J].中华流行病学杂志,2021,42(4):711-715 |
| 台州市2016-2018年新报告HIV/AIDS抗病毒治疗前HIV-1耐药及亚型流行特征分析 |
| HIV-1 drug resistance and subtypes in newly reported HIV/AIDS patients before antiretroviral therapy in Taizhou city, 2016-2018 |
| 收稿日期:2020-07-06 出版日期:2021-04-22 |
| DOI：10.3760/cma.j.cn112338-20200706-00926 |
| 中文关键词: 艾滋病病毒/艾滋病 亚型 耐药 |
| 英文关键词: HIV/AIDS Subtype Drug resistance |
| 基金项目:国家科技重大专项（2018ZX10721102-004）；上海市卫生健康委课题（GWTD2015S05） |
|
| 摘要点击次数: 2125 |
| 全文下载次数: 776 |
| 中文摘要: |
| 目的 了解台州市新报告HIV/AIDS抗病毒治疗（ART）前HIV-1耐药情况及亚型流行特点。方法 于2016年1月至2018年12月在台州市开展新报告HIV/AIDS在ART前HIV-1耐药的横断面调查，RT-PCR扩增获得HIV-1 pol基因片段并测序，提交序列至斯坦福大学耐药数据库，根据2014年WHO耐药监测指南的推荐标准，确定耐药突变位点以及HIV-1毒株对抗病毒药物的敏感性。结果 2016-2018年台州市新报告HIV/AIDS中成功获得HIV-1 pol基因区序列的研究对象806例，ART前HIV-1耐药率为2.9%（23/806），其中，非核苷类反转录酶抑制剂（NNRTIs）、核苷类反转录酶抑制剂（NRTIs）和蛋白酶抑制剂（PIs）耐药率分别为1.9%（15/806）、0.6%（5/806）和0.0%。2016-2018年新报告HIV/AIDS在ART前HIV-1耐药率依次分别为1.6%、1.8%和4.8%。NNRTIs和NRTIs耐药突变位点以K103 N（0.7%）和M184I/V（0.5%）为主。HIV-1亚型以CRF01_AE（42.7%，344/806）、CRF07_BC（28.9%，233/806）和CRF08_BC（11.2%，90/806）为主。同性性传播者HIV-1亚型以CRF01_AE（53.3%，136/255）和CRF07_BC（32.2%，82/255）为主；异性性传播者HIV-1亚型以CRF01_AE（37.7%，203/539）、CRF07_BC（27.5%，148/539）和CRF08_BC（16.1%，87/539）为主。结论 2016-2018年台州市新报告HIV/AIDS在ART前HIV-1耐药率处于低流行状态，但存在上升趋势，需加强对HIV-1耐药型毒株的监测工作。 |
| 英文摘要: |
| Objective To explore the HIV-1 drug resistance and subtypes in newly reported HIV/AIDS patients before antiretroviral therapy (ART) in Taizhou city. Methods A cross-sectional study of HIV-1 drug resistance was conducted among newly reported HIV/AIDS patients before ART in Taizhou from January 2016 to December 2018. HIV-1 pol gene sequences were obtained by RT-PCR. The sequences were submitted to the Stanford University drug resistance database. The drug resistance mutation and the sensitivity of HIV-1 strains to antiretroviral drugs were determined according to WHO Guidelines on HIV drug resistance surveillance of 2014. Results A total of 806 HIV-1 pol gene sequences were obtained successfully. The overall HIV-1 drug resistance rate was 2.9% (23/806), 1.9% for non-nucleoside reverse transcriptase inhibitors (NNRTIs), 0.6% for nucleoside reverse transcriptase inhibitors (NRTIs), and 0.0% for protease inhibitors (PIs), respectively. From 2016 to 2018, the HIV-1 drug resistance rate was 1.6%, 1.8%, and 4.8%, respectively. The resistance mutations of NNRTIs and NRTIs were mainly K103 N (0.7%) and M184I/V (0.5%). HIV-1 subtypes were mostly CRF01_AE (42.7%,344/806),CRF07_BC (28.9%,233/806) and CRF08_BC (11.2%,90/806).HIV-1 subtypes among homosexually transmitted infections were mostly CRF01_AE (53.3%, 136/255) and CRF07_BC (32.2%, 82/255), and HIV-1 subtypes among heterosexually transmitted infections were mainly CRF01_AE (37.7%, 203/539), CRF07_BC (27.5%, 148/539) and CRF08_BC (16.1%, 87/539). Conclusion HIV-1 drug resistance rate among newly reported HIV/AIDS patients before ART remained low in Taizhou during 2016 to 2018, an increasing trend seemed to be notifiable and warrants continuous surveillance of HIV-1 drug resistance. |
|
查看全文
Html全文
查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
